Adenosine A3 receptor

Adenosine A3 receptor
Identifiers
Symbols ADORA3; A3AR; AD026; bA552M11.5
External IDs OMIM: 600445 MGI: 104847 HomoloGene: 550 IUPHAR: A3 GeneCards: ADORA3 Gene
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez 140 11542
Ensembl ENSG00000121933 ENSMUSG00000000562
UniProt P33765 Q3U4C5
RefSeq (mRNA) NM_000677.3 NM_009631
RefSeq (protein) NP_000668.1 NP_033761
Location (UCSC) Chr 1:
112.03 – 112.11 Mb		 Chr 3:
106.03 – 106.04 Mb
PubMed search [1] [2]

The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor, but also denotes the human gene encoding it.

Contents

Function

Adenosine A3 receptors are G protein-coupled receptors that couple to Gi/Gq and are involved in a variety of intracellular signaling pathways and physiological functions. It mediates a sustained cardioprotective function during cardiac ischemia, it is involved in the inhibition of neutrophil degranulation in neutrophil-mediated tissue injury, it has been implicated in both neuroprotective and neurodegenerative effects, and it may also mediate both cell proliferation and cell death.

Gene

Multiple transcript variants encoding different isoforms have been found for this gene.[1]

Therapeutic implications

An adenosine A3 receptor agonist (CF-101) is in clinical trials for the treatment of rheumatoid arthritis.[2] In a mouse model of infarction the A3 selective agonist CP-532,903 protected against myocardial ischemia and reperfusion injury.[3]

Selective Ligands

A number of selective A3 ligands are available.[4][5][6][7][8][9][10][11][12][13][14][15]

Agonists/Positive Allosteric Modulators

Antagonists/Negative Allosteric Modulators

Inverse Agonists

References

  1. ^ "Entrez Gene: ADORA3 adenosine A3 receptor". http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=140. 
  2. ^ Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y, Rosner I, Rozenbaum M, Mader R, Adawi M, Caspi D, Tishler M, Langevitz P, Rubinow A, Friedman J, Green L, Tanay A, Ochaion A, Cohen S, Kerns WD, Cohn I, Fishman-Furman S, Farbstein M, Yehuda SB, Fishman P (January 2008). "Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial". J. Rheumatol. 35 (1): 41–8. PMID 18050382. http://www.jrheum.org/content/35/1/41.abstract. 
  3. ^ Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, Gross GJ, Kwok WM, Auchampach JA (January 2008). "The A3 adenosine receptor agonist CP-532,903 protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP sensitive potassium channel". J. Pharmacol. Exp. Ther. 324 (1): 234–43. doi:10.1124/jpet.107.127480. PMC 2435594. PMID 17906066. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2435594. 
  4. ^ Jeong LS, Lee HW, Jacobson KA, Lee SK, Chun MW (2005). "Development of potent and selective human A3 adenosine receptor agonists". Nucleic Acids Symposium Series (2004) 49 (49): 31–2. doi:10.1093/nass/49.1.31. PMID 17150618. 
  5. ^ Gao ZG, Jacobson KA (September 2007). "Emerging adenosine receptor agonists". Expert Opinion on Emerging Drugs 12 (3): 479–92. doi:10.1517/14728214.12.3.479. PMID 17874974. 
  6. ^ Kim SK, Gao ZG, Jeong LS, Jacobson KA (December 2006). "Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor". Journal of Molecular Graphics & Modelling 25 (4): 562–77. doi:10.1016/j.jmgm.2006.05.004. PMID 16793299. 
  7. ^ Ge ZD, Peart JN, Kreckler LM, Wan TC, Jacobson MA, Gross GJ, Auchampach JA (December 2006). "Cl-IB-MECA Reduces Ischemia/Reperfusion Injury in Mice by Activating the A3 Adenosine Receptor". The Journal of Pharmacology and Experimental Therapeutics 319 (3): 1200–10. doi:10.1124/jpet.106.111351. PMC 2430759. PMID 16985166. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2430759. 
  8. ^ Bevan N, Butchers PR, Cousins R, Coates J, Edgar EV, Morrison V, Sheehan MJ, Reeves J, Wilson DJ (June 2007). "Pharmacological characterisation and inhibitory effects of (2R,3R,4S,5R)-2-(6-amino-2-{[(1S)-2-hydroxy-1-(phenylmethyl)ethyl]amino}-9H-purin-9-yl)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-furandiol, a novel ligand that demonstrates both adenosine A(2A) receptor agonist and adenosine A(3) receptor antagonist activity". European Journal of Pharmacology 564 (1-3): 219–25. doi:10.1016/j.ejphar.2007.01.094. PMID 17382926. 
  9. ^ Priego EM, Pérez-Pérez MJ, von Frijtag Drabbe Kuenzel JK, de Vries H, Ijzerman AP, Camarasa MJ, Martín-Santamaría S (January 2008). "Selective human adenosine A3 antagonists based on pyrido[2,1-f]purine-2,4-diones: novel features of hA3 antagonist binding". ChemMedChem 3 (1): 111–9. doi:10.1002/cmdc.200700173. PMID 18000937. 
  10. ^ Jeong LS, Lee HW, Kim HO, Tosh DK, Pal S, Choi WJ, Gao ZG, Patel AR, Williams W, Jacobson KA, Kim HD (March 2008). "Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-N,N-dialkyluronamides as human A3 adenosine receptor antagonists". Bioorganic & Medicinal Chemistry Letters 18 (5): 1612–6. doi:10.1016/j.bmcl.2008.01.070. PMID 18255292. 
  11. ^ Cordeaux Y, Briddon SJ, Alexander SP, Kellam B, Hill SJ (March 2008). "Agonist-occupied A3 adenosine receptors exist within heterogeneous complexes in membrane microdomains of individual living cells". The FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology 22 (3): 850–60. doi:10.1096/fj.07-8180com. PMID 17959910. 
  12. ^ Gao ZG, Jacobson KA (April 2008). "Translocation of Arrestin Induced by Human A3 Adenosine Receptor Ligands in an Engineered Cell Line: Comparison with G Protein-dependent Pathways". Pharmacological Research : the Official Journal of the Italian Pharmacological Society 57 (4): 303–11. doi:10.1016/j.phrs.2008.02.008. PMC 2409065. PMID 18424164. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2409065. 
  13. ^ Miwatashi S, Arikawa Y, Matsumoto T, Uga K, Kanzaki N, Imai YN, Ohkawa S (August 2008). "Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as selective adenosine A3 antagonists". Chemical & Pharmaceutical Bulletin 56 (8): 1126–37. doi:10.1248/cpb.56.1126. PMID 18670113. http://joi.jlc.jst.go.jp/JST.JSTAGE/cpb/56.1126?from=PubMed. 
  14. ^ Gao ZG, Ye K, Göblyös A, Ijzerman AP, Jacobson KA (2008). "Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000". BMC Pharmacology 8: 20. doi:10.1186/1471-2210-8-20. PMC 2625337. PMID 19077268. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2625337. 
  15. ^ Bar-Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, Cohen S, Barer F, Zabutti A, Perez-Liz G, Del Valle L, Fishman P (August 2008). "The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways". International Journal of Oncology 33 (2): 287–95. PMID 18636149. http://www.spandidos-publications.com/ijo/article.jsp?article_id=ijo_33_2_287. 
  16. ^ Xiaowei Jin, Rebecca K. Shepherd, Brian R. Duling, and Joel Linden. "Inosine Binds to A3 Adenosine Receptors and Stimulates Mast Cell Degranulation"

Further reading

External links